NCR1 and neoplasm: A new generation of trifunctional NK-cell engager (NKCE) targeting two activating receptors NKp46 and CD16 on NK cells and a specific antigen on tumor cells has been reported to have more potent anti-tumor activity than clinical therapeutic antibodies in vitro and in vivo [176].